Skip to main content
NVDA-0.42%AAPL+1.10%GOOGL-2.28%MSFT-0.03%AMZN+0.04%TSM-0.83%SPCX-3.86%AVGO-1.13%META+1.40%TSLA-0.74%SKHY+7.05%MU-1.81%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.72%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-1.14%0005.HK-0.78%HSBA.L-1.25%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.14%CHFJPY-1.56%AUDJPY-1.45%USDJPY-1.33%EURJPY-1.24%CADJPY-1.23%GBPJPY-1.21%EURNZD+0.94%GBPNZD+0.93%NZDCAD-0.93%NZDUSD-0.84%AUDNZD+0.72%NZDCHF-0.61%USDNOK+0.56%EURNOK+0.49%GBPTRY+0.41%USDZAR+0.41%CHFNOK+0.38%EURZAR+0.34%GBPCHF+0.34%GBPHKD+0.32%EURCHF+0.32%CADCHF+0.32%GBPZAR+0.30%GBPMXN-0.28%USDSEK+0.28%SGDJPY+0.27%USDTHB+0.25%AUDCAD-0.25%AUDNOK+0.24%AUDDKK-0.24%USDCHF+0.24%GBPAUD+0.22%EURAUD+0.21%PLNJPY+0.21%EURSEK+0.20%USDPLN+0.19%AUDSGD-0.18%NOKJPY-0.16%USDILS+0.16%USDMXN+0.14%USDSGD+0.14%AUDUSD-0.12%GBPUSD+0.12%EURPLN+0.12%AUDCHF+0.11%USDTRY+0.11%CHFSEK+0.10%USDCAD-0.09%EURHKD-0.09%EURUSD+0.09%USDDKK+0.08%EURCZK-0.07%EURSGD+0.06%EURCNH-0.06%CHFSGD-0.05%USDCOP-0.04%NZDSGD+0.03%GBPSGD+0.02%NZDMXN+0.02%USDHKD+0.01%EURCAD-0.01%EURGBP0.00%EURDKK0.00%USDCNH0.00%GBPCAD0.00%HG1-4.22%XPTUSD-3.01%COFFEE-2.81%XAGUSD-2.26%GAGUSD-2.25%COCOA-1.75%SUGAR+1.74%COTTON+0.87%USOIL+0.66%C1+0.57%S1+0.53%UKOIL+0.48%BTCUSD-0.58%ETHUSD-0.30%USDTUSD-0.05%XRPUSD-1.49%SOLUSD-0.54%TRXUSDT+0.42%ZECUSDT-1.52%DOGEUSD-1.21%XMRUSDT-1.52%LINKUSD-0.12%XLMUSD-1.18%BCHUSDT-2.72%LTCUSD-1.74%UNIUSD-2.37%TONUSD+24.88%HBARUSDT-1.24%SUIUSD-1.30%TAOUSDT-1.22%AAVEUSD-2.15%DOTUSDT-2.27%ICPUSDT-1.40%ONDOUSDT-1.92%WLDUSDT-1.47%ATOMUSDT-2.92%ARBUSDT-1.30%JUPUSDT-2.53%INJUSDT-1.96%STXUSDT-3.43%FETUSDT-2.86%TIAUSDT-0.60%SEIUSDT-3.91%PYTHUSDT-1.20%IMXUSDT-2.27%WIFUSDT-2.93%GRTUSDT-2.81%OPUSDT-1.99%IOTAUSDT-3.03%POLUSDT-5.40%AXSUSDT-2.04%FARTCOINUSDT-2.58%EOSUSDT-0.06%DYDXUSDT-0.19%ORDIUSDT-0.37%GALAUSDT-3.09%NOTUSDT-0.68%RONINUSDT-0.71%NVDA-0.42%AAPL+1.10%GOOGL-2.28%MSFT-0.03%AMZN+0.04%TSM-0.83%SPCX-3.86%AVGO-1.13%META+1.40%TSLA-0.74%SKHY+7.05%MU-1.81%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.72%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-1.14%0005.HK-0.78%HSBA.L-1.25%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.14%CHFJPY-1.56%AUDJPY-1.45%USDJPY-1.33%EURJPY-1.24%CADJPY-1.23%GBPJPY-1.21%EURNZD+0.94%GBPNZD+0.93%NZDCAD-0.93%NZDUSD-0.84%AUDNZD+0.72%NZDCHF-0.61%USDNOK+0.56%EURNOK+0.49%GBPTRY+0.41%USDZAR+0.41%CHFNOK+0.38%EURZAR+0.34%GBPCHF+0.34%GBPHKD+0.32%EURCHF+0.32%CADCHF+0.32%GBPZAR+0.30%GBPMXN-0.28%USDSEK+0.28%SGDJPY+0.27%USDTHB+0.25%AUDCAD-0.25%AUDNOK+0.24%AUDDKK-0.24%USDCHF+0.24%GBPAUD+0.22%EURAUD+0.21%PLNJPY+0.21%EURSEK+0.20%USDPLN+0.19%AUDSGD-0.18%NOKJPY-0.16%USDILS+0.16%USDMXN+0.14%USDSGD+0.14%AUDUSD-0.12%GBPUSD+0.12%EURPLN+0.12%AUDCHF+0.11%USDTRY+0.11%CHFSEK+0.10%USDCAD-0.09%EURHKD-0.09%EURUSD+0.09%USDDKK+0.08%EURCZK-0.07%EURSGD+0.06%EURCNH-0.06%CHFSGD-0.05%USDCOP-0.04%NZDSGD+0.03%GBPSGD+0.02%NZDMXN+0.02%USDHKD+0.01%EURCAD-0.01%EURGBP0.00%EURDKK0.00%USDCNH0.00%GBPCAD0.00%HG1-4.22%XPTUSD-3.01%COFFEE-2.81%XAGUSD-2.26%GAGUSD-2.25%COCOA-1.75%SUGAR+1.74%COTTON+0.87%USOIL+0.66%C1+0.57%S1+0.53%UKOIL+0.48%BTCUSD-0.58%ETHUSD-0.30%USDTUSD-0.05%XRPUSD-1.49%SOLUSD-0.54%TRXUSDT+0.42%ZECUSDT-1.52%DOGEUSD-1.21%XMRUSDT-1.52%LINKUSD-0.12%XLMUSD-1.18%BCHUSDT-2.72%LTCUSD-1.74%UNIUSD-2.37%TONUSD+24.88%HBARUSDT-1.24%SUIUSD-1.30%TAOUSDT-1.22%AAVEUSD-2.15%DOTUSDT-2.27%ICPUSDT-1.40%ONDOUSDT-1.92%WLDUSDT-1.47%ATOMUSDT-2.92%ARBUSDT-1.30%JUPUSDT-2.53%INJUSDT-1.96%STXUSDT-3.43%FETUSDT-2.86%TIAUSDT-0.60%SEIUSDT-3.91%PYTHUSDT-1.20%IMXUSDT-2.27%WIFUSDT-2.93%GRTUSDT-2.81%OPUSDT-1.99%IOTAUSDT-3.03%POLUSDT-5.40%AXSUSDT-2.04%FARTCOINUSDT-2.58%EOSUSDT-0.06%DYDXUSDT-0.19%ORDIUSDT-0.37%GALAUSDT-3.09%NOTUSDT-0.68%RONINUSDT-0.71%
AB

ArriVent BioPharma, Inc. (AVBP)

NASDAQ • Healthcare

$29.79
-$0.49 (-1.6%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$30.02
Day Range$29.4 - $30.26
Avg. Volume (3M)419.3K
Market Cap$1.3B
52 Week Range
$17$35.83
Next EarningsIn 67 daysNov 16, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$163.7M
EPS (TTM)
-$3.68
ROA (TTM)
-41.48%
Current Ratio
14.16

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+10.3%Q1 2026-$0.78
-9.1%Q2 2026-$0.96
-6.3%Q3 2026-$1.05
Next

Nov 16

in 67 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -6.3%

ArriVent BioPharma trailed consensus on EPS in the second fiscal quarter of 2026, reported August 12, 2026, with preliminary results showing EPS of -$1.05 versus the -$0.99 estimate (difference -$0.06) and a GAAP net loss that widened 58.9% year over year to about -$49.9 million (from roughly -$31.4 million a year ago). The per-share loss also widened 16.7% from -$0.90 a year ago, alongside GAAP operating income of about -$52.7 million as the company continued advancing its oncology pipeline, including firmonertinib in EGFR-mutant non-small cell lung cancer. Cash use remained elevated, with operating cash flow of roughly -$39.6 million for the quarter. For the next period, consensus calls for EPS of -$1.07 on revenue of $800,000.00.

View full earnings history

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is a NASDAQ-listed healthcare company in biotechnology that identifies, develops, and aims to commercialize medicines for cancers with unmet medical needs. In qualitative terms, it is an early-stage oncology biopharma built around a small pipeline of targeted and antibody-based drug candidates.

Name
ArriVent BioPharma, Inc.
CEO
Zhengbin Yao
Website
arrivent.com
Industry
Healthcare
Year Founded
2021
Employees
77

Today's Snapshot

AI-generated

AVBP closed 1.6% lower at 29.79, while its sector was flat. Shares changed hands at about two-thirds of its usual level.

Trading Volume

Below 10d avg (387.4K)

267K

vs S&P 500 Today

Underperforming Market

-1.20%

Updated: September 9, 2026 at 20:09 UTC

Technical Indicators

2 Buy3 Neutral3 Sell
AVBP appears technically neutral with low trend strength and mixed momentum. ADX is low, reflecting a lack of clear directional conviction, while short-term momentum leans slightly negative even as RSI and other oscillators sit near neutral. The stock trades below several short- to mid-term moving averages yet remains above longer-term averages, and on-balance volume tilts toward selling pressure. Volatility is moderate by ATR and the classic pivot level is marginally above the current price, highlighting nearby resistance. Technical takeaway: Neutral.
All signals
  • EMA (5 indicators)$26.70 - $30.53
    Sell
  • RSI (14)45.63
    Neutral
  • Stochastic %K (14, 3, 3)61.56
    Neutral
  • MACD Level (12, 26)-0.10
    Neutral

Peers & Related Assets

ERASErasca, Inc.
$15.7-3.6%
IOVAIovance Biotherapeutics, Inc.
$8.43-3.1%
MBXMBX Biosciences, Inc. Common Stock
$62.91-0.1%
MGTXMeiraGTx Holdings plc
$13.26-2.0%
REPLReplimune Group, Inc.
$14.45-2.2%
ARVNArvinas, Inc.
$8.76-3.5%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.